Literature DB >> 27908882

Efficacy and safety of long-term RN-1 treatment to increase HbF in baboons.

Vinzon Ibanez1,2, Kestis Vaitkus1,2, Angela Rivers2,3, Robert Molokie1,2, Shuaiying Cui4, James Douglas Engel4, Joseph DeSimone1,2, Donald Lavelle1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27908882      PMCID： PMC5234223          DOI： 10.1182/blood-2016-10-746727

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  24 in total

1.  Effects of tetrahydrouridine on pharmacokinetics and pharmacodynamics of oral decitabine.

Authors:  Donald Lavelle; Kestis Vaitkus; Yonghua Ling; Maria A Ruiz; Reda Mahfouz; Kwok Peng Ng; Soledad Negrotto; Nicola Smith; Pramod Terse; Kory J Engelke; Joseph Covey; Kenneth K Chan; Joseph Desimone; Yogen Saunthararajah
Journal:  Blood       Date:  2011-12-07       Impact factor: 22.113

2.  Flow-cytometric analysis of platelet-membrane glycoprotein expression and platelet activation.

Authors:  Alison H Goodall; Jackie Appleby
Journal:  Methods Mol Biol       Date:  2004

3.  RN-1, a potent and selective lysine-specific demethylase 1 inhibitor, increases γ-globin expression, F reticulocytes, and F cells in a sickle cell disease mouse model.

Authors:  Angela Rivers; Kestis Vaitkus; Maria Armila Ruiz; Vinzon Ibanez; Ramasamy Jagadeeswaran; Tatiana Kouznetsova; Joseph DeSimone; Donald Lavelle
Journal:  Exp Hematol       Date:  2015-04-27       Impact factor: 3.084

4.  Embryonic epsilon and gamma globin genes of a prosimian primate (Galago crassicaudatus). Nucleotide and amino acid sequences, developmental regulation and phylogenetic footprints.

Authors:  D A Tagle; B F Koop; M Goodman; J L Slightom; D L Hess; R T Jones
Journal:  J Mol Biol       Date:  1988-09-20       Impact factor: 5.469

Review 5.  KDM1 histone lysine demethylases as targets for treatments of oncological and neurodegenerative disease.

Authors:  Tamara Maes; Cristina Mascaró; Alberto Ortega; Serena Lunardi; Filippo Ciceri; Tim C P Somervaille; Carlos Buesa
Journal:  Epigenomics       Date:  2015       Impact factor: 4.778

6.  Maintenance of elevated fetal hemoglobin levels by decitabine during dose interval treatment of sickle cell anemia.

Authors:  Joseph DeSimone; Mabel Koshy; Louise Dorn; Donald Lavelle; Linda Bressler; Robert Molokie; Nasrin Talischy
Journal:  Blood       Date:  2002-06-01       Impact factor: 22.113

7.  Prasugrel in children with sickle cell disease: pharmacokinetic and pharmacodynamic data from an open-label, adaptive-design, dose-ranging study.

Authors:  Lori Styles; Darell Heiselman; Lori E Heath; Brian A Moser; David S Small; Joseph A Jakubowski; Chunmei Zhou; Rupa Redding-Lallinger; Matthew M Heeney; Charles T Quinn; Sohail R Rana; Julie Kanter; Kenneth J Winters
Journal:  J Pediatr Hematol Oncol       Date:  2015-01       Impact factor: 1.289

8.  5-Azacytidine increases gamma-globin synthesis and reduces the proportion of dense cells in patients with sickle cell anemia.

Authors:  T J Ley; J DeSimone; C T Noguchi; P H Turner; A N Schechter; P Heller; A W Nienhuis
Journal:  Blood       Date:  1983-08       Impact factor: 22.113

9.  5-Azacytidine stimulates fetal hemoglobin synthesis in anemic baboons.

Authors:  J DeSimone; P Heller; L Hall; D Zwiers
Journal:  Proc Natl Acad Sci U S A       Date:  1982-07       Impact factor: 11.205

10.  Corepressor-dependent silencing of fetal hemoglobin expression by BCL11A.

Authors:  Jian Xu; Daniel E Bauer; Marc A Kerenyi; Thuy D Vo; Serena Hou; Yu-Jung Hsu; Huilan Yao; Jennifer J Trowbridge; Gail Mandel; Stuart H Orkin
Journal:  Proc Natl Acad Sci U S A       Date:  2013-04-01       Impact factor: 11.205
View more
  7 in total

Review 1.  Fetal hemoglobin in sickle cell anemia: The Arab-Indian haplotype and new therapeutic agents.

Authors:  Alawi H Habara; Elmutaz M Shaikho; Martin H Steinberg
Journal:  Am J Hematol       Date:  2017-08-17       Impact factor: 10.047

Review 2.  Potential role of LSD1 inhibitors in the treatment of sickle cell disease: a review of preclinical animal model data.

Authors:  Angela Rivers; Ramasamy Jagadeeswaran; Donald Lavelle
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2018-08-01       Impact factor: 3.619

Review 3.  Evolving treatment paradigms in sickle cell disease.

Authors:  Ramasamy Jagadeeswaran; Angela Rivers
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

4.  Oral administration of the LSD1 inhibitor ORY-3001 increases fetal hemoglobin in sickle cell mice and baboons.

Authors:  Angela Rivers; Kestis Vaitkus; Ramasamy Jagadeeswaran; Maria Armila Ruiz; Vinzon Ibanez; Filippo Ciceri; Fernando Cavalcanti; Robert E Molokie; Yogen Saunthararajah; James Douglas Engel; Joseph DeSimone; Donald Lavelle
Journal:  Exp Hematol       Date:  2018-08-17       Impact factor: 3.084

Review 5.  Epigenetic regulation of hemoglobin switching in non-human primates.

Authors:  Robert Molokie; Joseph DeSimone; Donald Lavelle
Journal:  Semin Hematol       Date:  2020-12-28       Impact factor: 3.851

6.  An erythroid-to-myeloid cell fate conversion is elicited by LSD1 inactivation.

Authors:  Lei Yu; Greggory Myers; Chia-Jui Ku; Emily Schneider; Yu Wang; Sharon A Singh; Natee Jearawiriyapaisarn; Andrew White; Takashi Moriguchi; Rami Khoriaty; Masayuki Yamamoto; Michael G Rosenfeld; Julien Pedron; John H Bushweller; Kim-Chew Lim; James Douglas Engel
Journal:  Blood       Date:  2021-11-04       Impact factor: 22.113

Review 7.  Targeting histone methyltransferase and demethylase in acute myeloid leukemia therapy.

Authors:  Germana Castelli; Elvira Pelosi; Ugo Testa
Journal:  Onco Targets Ther       Date:  2017-12-28       Impact factor: 4.147
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.